124 related articles for article (PubMed ID: 25158630)
1. Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.
Bauman WA; Cirnigliaro CM; La Fountaine MF; Martinez L; Kirshblum SC; Spungen AM
J Bone Miner Metab; 2015 Jul; 33(4):410-21. PubMed ID: 25158630
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density after spinal cord injury: a reliable method for knee measurement.
Shields RK; Schlechte J; Dudley-Javoroski S; Zwart BD; Clark SD; Grant SA; Mattiace VM
Arch Phys Med Rehabil; 2005 Oct; 86(10):1969-73. PubMed ID: 16213240
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
[TBL] [Abstract][Full Text] [Related]
4. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies.
Harding AK; W-Dahl A; Geijer M; Toksvig-Larsen S; Tägil M
Acta Orthop; 2011 Aug; 82(4):465-70. PubMed ID: 21689069
[TBL] [Abstract][Full Text] [Related]
5. Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study.
Morse LR; Nguyen N; Battaglino RA; Guarino AJ; Gagnon DR; Zafonte R; Garshick E
Osteoporos Int; 2016 Dec; 27(12):3503-3511. PubMed ID: 27412619
[TBL] [Abstract][Full Text] [Related]
6. Regional and temporal variation in bone loss during the first year following spinal cord injury.
Abdelrahman S; Purcell M; Rantalainen T; Coupaud S; Ireland A
Bone; 2023 Jun; 171():116726. PubMed ID: 36871898
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal evaluation of mouse hind limb bone loss after spinal cord injury using novel, in vivo, methodology.
McManus MM; Grill RJ
J Vis Exp; 2011 Dec; (58):. PubMed ID: 22158515
[TBL] [Abstract][Full Text] [Related]
8. Delayed Systemic Treatment with Cannabinoid Receptor 2 Agonist Mitigates Spinal Cord Injury-Induced Osteoporosis More Than Acute Treatment Directly after Injury.
Tucci MA; Pride Y; Strickland S; Marocho SMS; Jackson RJ; Jefferson JR; Chade AR; Grill RJ; Grayson BE
Neurotrauma Rep; 2021; 2(1):270-284. PubMed ID: 34223557
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid.
Tantavisut S; Tanavalee A; Thanakit V; Ngarmukos S; Wilairatana V; Wangroongsub Y
Clin Orthop Surg; 2014 Sep; 6(3):358-60. PubMed ID: 25177464
[TBL] [Abstract][Full Text] [Related]
10. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats.
Li GW; Xu Z; Chang SX; Zhou L; Wang XY; Nian H; Shi X
Endocrinology; 2014 Dec; 155(12):4731-8. PubMed ID: 25243855
[TBL] [Abstract][Full Text] [Related]
11. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Cosman F; Cauley JA; Eastell R; Boonen S; Palermo L; Reid IR; Cummings SR; Black DM
J Clin Endocrinol Metab; 2014 Dec; 99(12):4546-54. PubMed ID: 25215556
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Urol; 2014 Nov; 11(11):599. PubMed ID: 25201618
[No Abstract] [Full Text] [Related]
13. Prostate cancer: Androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Clin Oncol; 2014 Oct; 11(10):559. PubMed ID: 25200412
[No Abstract] [Full Text] [Related]
14. Breast cancer: Zoledronic acid--more than just a bone drug.
Mathew A; Brufsky A
Nat Rev Clin Oncol; 2014 Oct; 11(10):564-5. PubMed ID: 25200411
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies.
Lézot F; Chesneau J; Battaglia S; Brion R; Castaneda B; Farges JC; Heymann D; Rédini F
Bone; 2014 Nov; 68():146-52. PubMed ID: 25193159
[TBL] [Abstract][Full Text] [Related]
16. Acute effect of zoledronic acid on the risk of cardiac dysrhythmias.
Cipriani C; Castro C; Curione M; Piemonte S; Biamonte F; Savoriti C; Pepe J; De Lucia F; Clementelli C; Nieddu L; Minisola S
Intern Emerg Med; 2015 Mar; 10(2):151-6. PubMed ID: 25190623
[TBL] [Abstract][Full Text] [Related]
17. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.
Ghosh PM; Gao AC
Endocr Relat Cancer; 2014 Oct; 21(5):C11-4. PubMed ID: 25183429
[TBL] [Abstract][Full Text] [Related]
19. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
